Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.
A number of diseases are treated by passive administration of human proteins. Human coagulation factor VIII (FVIII) is one such protein which is administered to hemophilia A patients in order to manage and treat hemorrhagic incidences. This mode of therapy suffers from the side effect of generating anti-FVIII antibodies (inhibitors) which neutralizes the function of the infused FVIII. At a time when efficient viral screening procedures are at place, development of inhibitors poses the greatest threat to such a therapy. Various predisposing factors, both patient and product-related, are responsible for the development of inhibitory antibodies. A proper understanding of these "risk-factors" would eventually help to better design therapeutic regimen to tackle hemophilia A.
Dasgupta
Suryasarathi
S
INSERM, UMR S 872, Les Cordeliers, Paris F-75006, France.
Navarrete
Ana-Maria
AM
Delignat
Sandrine
S
Wootla
Bharath
B
Andre
Sebastien
S
Nagaraja
Valakunja
V
Lacroix-Desmazes
Sebastien
S
Kaveri
Srinivas V
SV
D000818:Animals; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D005169:Factor VIII / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D012307:Risk Factors; D016896:Treatment Outcome
D000906:Antibodies; C078147:F8 protein, human; D005169:Factor VIII